Ferrous Sulfate vs Iron Bisglycinate: Which Iron Form to Buy

Aug 29, 2026 · 7 min · ferrous sulfate vs iron bisglycinate

Dr Cath

Chemistry PhD · evidence-based supplementation

Ferrous Sulfate vs Iron Bisglycinate: Which Iron Form to Buy

Which should you buy, ferrous sulfate or iron bisglycinate?

For most people correcting iron deficiency, ferrous sulfate remains the sensible default: it is cheap, it is the form the bulk of the efficacy data sits on, and at a therapeutic dose it raises iron stores. Choose iron bisglycinate when the gastrointestinal cost of ferrous sulfate is the thing actually stopping you from taking iron at all – that is the situation where the more expensive form earns its place, and it is a narrow one.

The claim you will see repeated on bisglycinate labels – that it is "more bioavailable" and therefore better – is partly true and partly an overreach, and the two halves need separating before you spend money.

Both deliver elemental iron; the chemistry around that iron differs, and so does the depth of evidence behind each.

Ferrous sulfate is a simple iron(II) salt. In the acidic stomach it dissociates, and the free ferrous ion is what your intestine absorbs. This is the workhorse form – the one most classic dose-response and efficacy work was done on, and the reference against which newer forms are measured.

Iron bisglycinate (ferrous bisglycinate) is an amino-acid chelate: one iron atom held between two glycine molecules. The design intent is that the chelate protects the iron from the dietary factors – phytates, polyphenols, calcium – that suppress absorption of the free ion, and that it delivers less unabsorbed iron to the gut. That is a genuine, understood chemical difference, not a marketing invention.

The important point for a buyer: these are two different iron compounds with two different evidence bases. Chemical plausibility that the chelate absorbs better is not the same as a trial showing it produces a better clinical result at a matched dose. Those are separate tiers of evidence, and the label tends to quote the first while implying the second.

Not to be confused with: ferrous bisglycinate (the chelate) and ferrous glycine sulfate are different compounds, despite both containing glycine. A result reported for one does not carry over to the other.

What does the absorption and outcome data actually show?

Here the two halves of the marketing claim come apart.

The bioavailability advantage is real as chemistry. A chelated iron shielded from dietary inhibitors is expected to be absorbed more efficiently per milligram than the free ferrous ion, particularly when taken with food. This is established, understood chemistry. It is why a lower dose of bisglycinate can be discussed at all.

The outcome question is where you should read carefully. The relevant test is not "does more iron get absorbed" – a surrogate – but "does the form change ferritin, or correct anaemia, in a way that matters." On that question a randomised controlled trial in Cambodian women asked whether a lower dose of the more bioavailable iron (ferrous bisglycinate) was noninferior to a higher dose of ferrous sulfate for raising ferritin, while also looking at gut inflammation and enteropathogen detection. The design says what the chelate is really offering: not more iron from the same milligrams, but possibly enough iron from fewer. The result went against it. Over twelve weeks, 18 mg of ferrous bisglycinate did not raise ferritin as effectively as 60 mg of ferrous sulfate, and the two forms did not differ on the gut inflammation and enteropathogen measures either. The women studied were largely iron-replete, which limits how far the ferritin finding travels to someone who is genuinely deficient – but this is the head-to-head measurement that exists, and it does not support the lower-dose-because-better-absorbed argument printed on labels.

What this leaves you with: the bioavailability premise is supported as chemistry, and the one human comparison that exists did not show a lower dose of the chelate matching a standard dose of the salt. What is not established is a broad, replicated clinical superiority of bisglycinate over ferrous sulfate across the general iron-deficient population. The comparisons that exist are specific – particular populations, particular comparators, particular doses – and do not license the flat claim that the chelate is simply the better product for everyone.

What are the drawbacks of each?

Ferrous sulfate's cost is tolerability. Unabsorbed ferrous ion in the gut is associated with nausea, constipation and abdominal discomfort in a meaningful share of users. For many people this is the real reason iron supplementation fails – not that the iron does not work, but that they stop taking it. The gut-inflammation and enteropathogen measures in the Cambodian trial exist precisely because delivering large amounts of unabsorbed iron to the intestine is not biologically neutral.

Bisglycinate's cost is price and thinner evidence. It is more expensive per unit of elemental iron, and its efficacy record – while it includes real trials – is narrower than the decades of data behind ferrous sulfate. "Less studied" is not "worse," but it does mean you are paying a premium partly for a chemistry argument rather than for an equivalently deep outcome record.

How the two compare

Criterion Ferrous sulfate Iron bisglycinate Evidence strength Raises iron stores at a therapeutic dose Yes Yes at a therapeutic dose; a lower dose did not match standard-dose sulfate Direct human outcome evidence, broader for sulfate Better absorption per milligram with food Baseline Expected higher Mechanistically plausible / established chemistry Less unabsorbed iron and gut disturbance More unabsorbed iron Designed to reduce it Design rationale; the trial that measured gut markers found no difference Gastrointestinal tolerability Poorer for many Often reported better Mechanistically plausible, tolerability data limited Cost per unit iron Low Higher Established Depth of efficacy record Extensive Narrower Established

Who should choose which?

Ferrous sulfate suits most people starting iron correction who tolerate it: it is the cheapest form with the deepest outcome record, and there is no demonstrated reason for the average iron-deficient adult to pay more.

Iron bisglycinate suits the person for whom tolerability is the binding constraint – someone who has genuinely tried a standard salt and abandoned it because of gut symptoms, or who needs to take iron with food and wants to blunt the dietary suppression of absorption. Here the more bioavailable, gentler-by-design form addresses the actual failure point. The claim that it leaves less unabsorbed iron in the gut is a design rationale, not a measured advantage: the trial that looked found no difference in gut markers.

Two criteria that should not drive the decision: the bare word "bioavailable" on the label, which describes a surrogate and not a proven clinical edge; and the assumption that a newer, pricier form must be better, which the comparative human data do not establish.

The point at which this becomes a clinician's decision, not a shopping one: iron deficiency should be confirmed and its cause investigated before you supplement long-term, and dosing during pregnancy or with known gastrointestinal disease belongs with a doctor. Iron is not a supplement to take speculatively – excess is harmful, and the reason to check ferritin first is as much about not over-treating as about treating.

Verdict

This comparison is settled with exceptions. For the general iron-deficient adult, ferrous sulfate is the rational default on cost and evidence depth, and bisglycinate's headline advantage is a real chemistry claim that has not translated into a demonstrated across-the-board clinical superiority. The exception is genuine and specific: if ferrous sulfate's gastrointestinal cost is what actually stops you taking iron, bisglycinate is a defensible upgrade, because a form you tolerate beats a cheaper form you abandon. What would settle the general question is a large head-to-head trial at matched clinical endpoints across an unselected iron-deficient population – and that broad comparison is not what the current evidence provides.